Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




Endogenous Interference Impairs Arterial Blood Gas Analysis

By LabMedica International staff writers
Posted on 20 Mar 2012
Blood samples that show hemolysis, lipemia, or icterus may be unsuitable for arterial blood gas analysis (ABG) as these indices affect the results. More...


The modern ABG analyzers enables rapid analysis of traditional blood gas elements such as pH, partial pressure of carbon dioxide (pCO2) and oxygen partial pressure (pO2), and oxygen saturation as well as clinical chemistry parameters, all of which rely on the quality of the specimens.

Scientists at the University of Verona (Italy) analyzed 478 ABG specimens received in their laboratory throughout a two-month study period. The serum indices (SI) were assessed after all routine and stat samples referred for ABG analysis to the clinical laboratory using RAPIDPoint 400/405 Systems, Arterial Blood Gas Analyzer were completed. The SI of plasma was then assessed on the Cobas C501 after centrifugation. Interference cut-off values were 60 for Hemolysis Index (HI, i.e., cut-off of visible hemolysis), 30 for Lipemia Index (LI, i.e. Lipemic index is determined by the turbidity qualitatively with no units) and two for Icteric Index (II).

Out of a total of 478 ABG specimens received in the laboratory throughout the two month study period, 132 (27.6%) displayed at least one SI exceeding the cut-off. This could be further categorized as 44/162 (27.2%) from the emergency department, and 88/316, (28.6%) from the clinical wards. In particular 17 samples (4%) were characterized by HI exceeding 60, 52 samples (11%) by a LI exceeding 30, and 63 (13%) by II exceeding two. The frequency of hemolyzed specimens referred from the emergency department was double that of samples referred from the clinical wards.

The RAPIDPoint 400/405 Systems, Arterial Blood Gas Analyzer is a product of Siemens Medical Solutions (Munich, Germany) and the Cobas C501 is manufactured by Roche (Basle, Switzerland). The authors concluded that that a significant number of AGB specimens sent to their laboratory were characterized by elevated values of the SI, which could make them unreliable for testing. In particular, the frequency of HI greater than 60 was remarkably higher for samples referred from the emergency department than in those from the clinical wards, thereby confirming the trend already observed for clinical chemistry, immunochemistry, and coagulation testing. The study was published in the March 2012 issue of the journal Clinical Biochemistry.

Related Links:

University of Verona
Siemens Medical Solutions
Roche



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: Tumor DNA is extracted from a pathology sample, and normal DNA is extracted from the buffy coat. Both samples undergo WGS to generate the patient-specific mutational signature. At each follow-up, ctDNA extracted from plasma undergoes WGS and is analyzed using a patient-derived signature and an artificial intelligence (AI) pattern recognition algorithm. FFPE: formalin fixed, paraffin embedded. (Snuderl M, Smadbeck J, Wilkins R, et al. The Journal of Molecular Diagnostics, 2026. DOI: 10.1016/j.jmoldx.2026.07.003)

Liquid Biopsy Detects Lung Cancer Recurrence Signals Months Before Imaging

Non-small cell lung cancer (NSCLC) is the most common type of lung cancer and remains a major cause of cancer-related death. Early-stage tumors are often treated surgically, but recurrence can still occur... Read more

Immunology

view channel
Image Credit: iStock

Antibody Profiling Predicts Inflammatory Bowel Disease Years Before Diagnosis

Inflammatory bowel disease (IBD), which includes Crohn’s disease and ulcerative colitis, involves abnormal immune responses that cause persistent inflammation and damage in the digestive system.... Read more

Pathology

view channel
Image: HETA Quality Control identifies slide quality issues before analysis, while HETA Tumor Detect annotates tumor regions and flags slides likely to contain tumor during scanning. (Photo courtesy of Aignostics)

AI Pathology Platform Targets Workflow Delays and Molecular Test Failures

Pathology laboratories often rely on visual review of tissue slides to assess quality, identify tumors, count mitoses, and estimate tumor content. These tasks can be time-consuming and vary between readers,... Read more

Technology

view channel
Image: Signals LabGistics uses AI to turn natural-language instructions and SOPs into coordinated scientific workflows, helping connect teams, systems, and processes. (Photo courtesy of Revvity)

New AI-Powered System Aims to Streamline Laboratory and Manufacturing Workflows

Scientific laboratories supporting drug development, biotechnology, and materials research increasingly rely on coordinated digital workflows to move data, samples, and activities across teams.... Read more

Industry

view channel
Image: The acquisition of Reveal Genomics would expand Hologic’s oncology diagnostics portfolio to support treatment decisions for more women with breast cancer.

Hologic to Broaden Breast Cancer Testing Portfolio Through Reveal Genomics Acquisition

Hologic (Marlborough, MA, USA) has signed a definitive agreement to acquire Reveal Genomics (Barcelona, Spain), a precision oncology company developing genomic diagnostic tests to help personalize cancer treatment.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.